Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Quantitative analysis of striatal dopamine D2 receptors with I-123-iodolisuride SPECT in degenerative extrapyramidal diseases
Autore:
Prunier, C; Tranquart, F; Cottier, JP; Giraudeau, B; Chalon, S; Guilloteau, D; De Toffol, B; Chossat, F; Autret, A; Besnard, JC; Baulieu, JL;
Indirizzi:
Univ Hosp Tours, Dept Nucl Med, Tours, France Univ Hosp Tours Tours France v Hosp Tours, Dept Nucl Med, Tours, France
Titolo Testata:
NUCLEAR MEDICINE COMMUNICATIONS
fascicolo: 11, volume: 22, anno: 2001,
pagine: 1207 - 1214
SICI:
0143-3636(200111)22:11<1207:QAOSDD>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROGRESSIVE SUPRANUCLEAR PALSY; MULTIPLE-SYSTEM ATROPHY; PARKINSONS-DISEASE; C-11 RACLOPRIDE; STRIATONIGRAL DEGENERATION; DIFFERENTIAL-DIAGNOSIS; CLINICAL-DIAGNOSIS; BINDING; PET; IODOLISURIDE;
Keywords:
Parkinson's disease; diagnosis; SPECT; I-123-iodolisuride; dopamine D2 receptors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Prunier, C Bretonneau Hosp, Dept Nucl Med, 2bis Blvd Tonnele, F-37044 Tours, France Bretonneau Hosp 2bis Blvd Tonnele Tours France F-37044 France
Citazione:
C. Prunier et al., "Quantitative analysis of striatal dopamine D2 receptors with I-123-iodolisuride SPECT in degenerative extrapyramidal diseases", NUCL MED C, 22(11), 2001, pp. 1207-1214

Abstract

I-123-Iodolisuride has high specific affinity for binding on dopamine D2 receptors in the striatum and has been used in a few single photon emission computed tomography (SPECT) studies of extrapyramidal disorders. The diagnosis of Parkinson's disease (PD) is very difficult in the first 5 years of evolution, with 15-25% false positive diagnoses. The aim of this study was therefore to determine the value of iodolisuride SPECT in discriminating Parkinson's from the most frequent Parkinson-plus syndromes (PPS). Seventeen patients with an extrapyramidal syndrome had a SPECT examination 1 h after injection of 180-185 MBq of I-123-iodolisuride. They were followed under dopaminergic treatment for at least 2 years. After 2 years, they were separated in two groups according to specific clinical criteria and sensitivity to dopaminergic treatment: nine patients had PD (age = 59.8+/-8.8 years; Hoehnand Yahr = 1.8+/-0.7; evolution = 4.3+/-3 years) and eight had PPS (age = 71.6+/-7.3 years; Hoehn and Yahr = 2.9+/-2.0; evolution = 4.1+/-1.5 years). The binding potential of iodolisuride in the striatum was assessed by considering the striatum (S)/occipital lobe (O) ratio at the pseudo-equilibrium1 h after injection. The S/O ratio was statistically different between PD and PPS (1.97+/-0.3 vs 1.65+/-0.2 (P < 0.02)). Iodolisuride SPECT could differentiate both groups with a sensitivity of 88.8% and a specificity of 75%. Iodolisuride is a good specific D2 receptor ligand for SPECT and complements specific clinical criteria for the diagnosis of Parkinson's disease anddifferentiation between different extrapyramidal disorders. ((C) 2001 Lippincott Williams & Wilkins).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 21:29:28